Immunic, Inc. (IMUX)
NASDAQ:IMUX
IMUX Stock Chart & Stats
$1.03
-$0.01(-1.34%)
At close: 4:00 PM EST
$1.03
-$0.01(-1.34%)
Day’s Range― - ―
52-Week Range$0.51 - $1.51
Previous CloseN/A
Volume261.21K
Average Volume (3M)3.07M
Market Cap
$134.38M
Enterprise Value$94.74M
Total Cash (Recent Filing)$15.48M
Total Debt (Recent Filing)$684.00K
Price to Earnings (P/E)―
Beta0.93
Next Earnings
May 07, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding130,464,830
10 Day Avg. Volume2,092,158
30 Day Avg. Volume3,065,532
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)-124.52
Price to Sales (P/S)0.00
P/FCF Ratio-9.67
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.26K
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$5.00Price Target Upside385.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Mechanism And Safety ProfileDual DHODH inhibition combined with Nurr1 activation may provide nerve-cell protection while avoiding the liver toxicity associated with some oral competitors, supporting a differentiated safety profile.
Pivotal Trial ResultsTopline readouts from the fully enrolled ENSURE late-stage trials could validate vidofludimus calcium's clinical benefit and trigger a material re-rating if results demonstrate superiority versus placebo.
Progressive Multiple Sclerosis And Antiviral PotentialEncouraging mid-stage results in progressive multiple sclerosis patients without MRI-visible inflammation, together with reported antiviral activity against Epstein-Barr virus, point to potential benefits beyond relapse suppression.
Bears Say
Competitive RiskUncertainty about clear differentiation from numerous competing oral multiple sclerosis therapies, along with upcoming rival readouts, could curb market uptake even with positive clinical signals.
Funding And Dilution RiskA remaining financing overhang and limited internal funding increase the likelihood of dilutive financings or a dependence on partnerships, which could weigh on the stock.
Valuation PressureAnalyst price target reductions after adjusting share count and launch assumptions highlight downside risk to valuation if commercialization and penetration fall short of expectations.
Immunic News
IMUX FAQ
What was Immunic, Inc.’s price range in the past 12 months?
Immunic, Inc. lowest stock price was $0.51 and its highest was $1.51 in the past 12 months.
What is Immunic, Inc.’s market cap?
Immunic, Inc.’s market cap is $134.38M.
When is Immunic, Inc.’s upcoming earnings report date?
Immunic, Inc.’s upcoming earnings report date is May 07, 2026 which is in 36 days.
How were Immunic, Inc.’s earnings last quarter?
Immunic, Inc. released its earnings results on Feb 26, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.01.
Is Immunic, Inc. overvalued?
According to Wall Street analysts Immunic, Inc.’s price is currently Undervalued.
Does Immunic, Inc. pay dividends?
Immunic, Inc. does not currently pay dividends.
What is Immunic, Inc.’s EPS estimate?
Immunic, Inc.’s EPS estimate is -0.08.
How many shares outstanding does Immunic, Inc. have?
Immunic, Inc. has 130,464,830 shares outstanding.
What happened to Immunic, Inc.’s price movement after its last earnings report?
Immunic, Inc. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went up 4.066%.
Which hedge fund is a major shareholder of Immunic, Inc.?
Currently, no hedge funds are holding shares in IMUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (385.44% Upside)
$5.00 (385.44% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.09%
12-Months-Change
Fundamentals
Return on Equity
-1197.81%
Trailing 12-Months
Asset Growth
-41.15%
Trailing 12-Months
Company Description
Immunic, Inc.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
IMUX Stock 12 Month Forecast
Average Price Target
$5.00
▲(385.44% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
0.97% Insiders
3.96% Mutual Funds
17.98% Other Institutional Investors
73.45% Public Companies and Individual Investors